To the best of our knowledge, there are no published data on the historical and recent use of CGM in clinical trials of pharmacological agents used in the treatment of diabetes. We analyzed 2,032 clinical trials of 40 antihyperglycemic therapies currently on the market with a study start date between 1 January 2000 and 31 December 2019. According to ClinicalTrials.gov, 119 (5.9%) of these trials used CGM. CGM usage in clinical trials has increased over time, rising from <5% before 2005 to 12.5% in 2019. However, it is still low given its inclusion in the American Diabetes Association’s latest guidelines and known limitations of A1C for assessing ongoing diabetes care.
Despite the growing momentum behind a movement to augment adoption
of continuous glucose monitoring (CGM) in clinical practice and investigation,
to the best of our knowledge, there are no published data on the historical and
recent use of CGM in clinical trials of pharmacologic agents used in the
treatment of diabetes. We analyzed 2,032 clinical trials of 40 diabetes
therapies currently on the market with a study start date between 1 January
2000 and 31 December 2019. According to ClinicalTrials.gov listings, 119 (5.9%)
of these trials used CGM. CGM usage in clinical trials has increased over time,
rising from <5% before 2005 to 12.5% in 2019. However, it is still low given
its inclusion in the American Diabetes’s Association’s latest guidelines and known
limitations of A1C for assessing ongoing diabetes care.
Despite the growing momentum behind a movement to augment adoption
of continuous glucose monitoring (CGM) in clinical practice and investigation,
to the best of our knowledge, there are no published data on the historical and
recent use of CGM in clinical trials of pharmacologic agents used in the
treatment of diabetes. We analyzed 2,032 clinical trials of 40 diabetes
therapies currently on the market with a study start date between 1 January
2000 and 31 December 2019. According to ClinicalTrials.gov listings, 119 (5.9%)
of these trials used CGM. CGM usage in clinical trials has increased over time,
rising from <5% before 2005 to 12.5% in 2019. However, it is still low given
its inclusion in the American Diabetes’s Association’s latest guidelines and known
limitations of A1C for assessing ongoing diabetes care.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.